ALPERIN BARRY J
Known title: DirectorCIK: 0001194358
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Henry Schein Extends Credit Facility Amid Market Growth Projections. Henry Schein recently extended its credit facility, a move that supports its financial flexibility. This corporate action comes as the dental implants market is projected to grow from $12.79 billion in 2026 to $17.67 billion by 2031. The company also marked 25 years of its Henry Schein Cares initiative. These developments provide context for the stock's current position near its support level.
Transaction History
| JEF | ▲ Buy | Grant | 6,583 | $205K | 3/29/2023 | View on chart |
| JEF | ▲ Buy | Grant | 265 | $7K | 6/28/2022 | View on chart |
| JEF | ▲ Buy | Grant | 5,697 | $190K | 3/29/2022 | View on chart |
| HSIC | ▲ Buy | Grant | 2,028 | $0 | 3/16/2022 | View on chart |
| HSIC | ▼ Sell | Tax Withholding | 613 | $53K | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Jefferies Q3 shows record banking revenue but weaker trading
Jefferies reported third-quarter results where record investment banking and equities revenue helped offset softer performance in asset management and fixed income. The firm also expanded its partnership with SMBC to support growth in Japan and highlighted specific opportunities in biotech and clean energy sectors. These developments provide context for the stock's current trading levels and its valuation relative to analyst targets.
Jefferies Q3 shows record banking revenue but weaker trading. Jefferies reported third-quarter results where record investment banking and equities revenue helped offset softer performance in asset management and fixed income. The firm also expanded its partnership with SMBC to support growth in Japan and highlighted specific opportunities in biotech and clean energy sectors. These developments provide context for the stock's current trading levels and its valuation relative to analyst targets.